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Abstract
Background: The number of tumor suppressor genes for which germline mutations have been linked to cancer
risk is steadily increasing. However, while recent reports have linked constitutional normal tissue promoter
methylation of BRCA1 and MLH1 to ovarian and colon cancer risk, the role of epigenetic alterations as cancer risk
factors remains largely unknown, presenting an important area for future research. Currently, we lack fast and
sensitive methods for assessment of promoter methylation status across known tumor suppressor genes.
Results: In this paper, we present a novel NGS-based approach assessing promoter methylation status across a
large panel of defined tumor suppressor genes to base-pair resolution. The method omits the limitations related to
commonly used array-approaches. Our panel includes 565 target regions covering the promoters of 283 defined
tumor suppressors, selected by pre-specified criteria, and was applied for rapid targeted methylation-specific NGS.
The feasibility of the method was assessed by analyzing normal tissue DNA (white blood cells, WBC) samples from
34 healthy postmenopausal women and by performing preliminary assessment of the methylation landscape of
tumor suppressors in these individuals. The mean target coverage was 189.6x providing a sensitivity of 0.53%,
sufficient for promoter methylation assessment of low-level methylated genes like BRCA1. Within this limited test-
set, we detected 206 regions located in the promoters of 149 genes to be differentially methylated (hyper- or hypo-)
at > 99% confidence level. Seven target regions in gene promoters (CIITA, RASSF1, CHN1, PDCD1LG2, GSTP1, XPA,
and ZNF668) were found to be hyper-methylated in a minority of individuals, with a > 20 percent point difference
in mean methylation across the region between individuals. In an exploratory hierarchical clustering analysis, we
found that the individuals analyzed may be grouped into two main groups based on their WBC methylation profile
across the 283 tumor suppressor gene promoters.
Conclusions: Methylation-specific NGS of our tumor suppressor panel, with detailed assessment of differential
methylation in healthy individuals, presents a feasible method for identification of novel epigenetic risk factors for
cancer.
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Introduction
The number of tumor suppressor genes for which germ-
line mutations are linked to elevated cancer risk is stead-
ily increasing [1–3]. Mutations across different genes
present a continuum of penetrance, ranging from mod-
erately to massively elevated risk of different cancer
forms. Further, while mutations in some genes (so far)
are restricted to increased risk of a single, or a few can-
cer forms, mutations in other genes may increase the
risk of multiple different types of cancer [4, 5].
Some of the best described “classical” high penetrance
genes include BRCA1/2, for which germline mutations
are associated with an elevated risk of ovarian and breast
cancer [6], MLH1/MSH2 linked to colorectal cancer [7],
CDKN2A and RB1, associated with melanoma and ret-
inoblastoma, respectively [8–10], as well as TP53, associ-
ated with the Li-Fraumeni syndrome with an elevated
risk for multiple cancer forms [11]. However, the list of
genes for which germline mutations are ascertained to
confer cancer risk is continuously increasing due to ap-
plication of massive parallel sequencing [12, 13]. Still, for
many families with multiple cases of a specific tumor
form (like breast, ovary, or melanomas), no pathogenic
germline gene variant has been identified.
Epigenetic gene inactivation may occur through differ-
ent mechanisms [14, 15]. So far, promoter methylation
is the best studied of all the epigenetic modifications,
and such methylation is well established as a mechanism
of inactivation of tumor suppressor genes. While many
germline mutations affecting tumor suppressor genes
are well studied as cancer risk factors, knowledge regard-
ing constitutional epigenetic inactivation [16] as a poten-
tial cancer risk factor remains limited. Somatic promotor
methylation in tumor suppressor genes is a common
event in cancer [17], but the role of aberrant epigenetic
events, or constitutional promoter methylation of tumor
suppressor genes in normal cells as potential cancer risk
factors, remains largely unexplored. While mosaic
methylation of the MLH1 gene in normal leukocytes has
been observed in colorectal cancer patients [18, 19] and
a haplotype leading to secondary constitutional methyla-
tion in the MGM2 promoter [20] has been found in a
cancer-prone family [21], in general, data on normal tis-
sue methylation patterns and cancer risk are scarce [22].
Recently, in a large study, we reported low-grade mo-
saic (< 10% of alleles) normal tissue BRCA1 promoter
methylation to confer a significantly increased risk of
high-grade serous ovarian cancer (HGSOC) [23]. In our
study, we found > 4% of healthy adult females in a Cau-
casian population to harbor mosaic BRCA1 promoter
methylation in their normal white blood cells (WBC).
Individuals carrying such methylation had a 2-3 fold in-
creased risk of HGSOC. Importantly, WBC BRCA1 pro-
moter methylation was strongly associated with
corresponding methylation in other normal tissues, and,
in HGSOC patients, also associated with methylation in
the tumor. Taken together, this indicated that methyl-
ated normal cells in the ovary may act as tumor
precursors.
Based on these results and the findings of others [19,
24–29], we hypothesized that additional tumor suppres-
sors could be hyper-methylated in normal cells, thereby
causing an elevated risk for certain cancer forms within
subgroups of healthy individuals in the general popula-
tion [30].
To explore such a hypothesis, there is a need for im-
proved methodologies. Although methylation status may
be analyzed by conventional arrays, such assessments are
limited to the selection of CpGs covered by the array
probes. These selected CpGs may not necessarily repre-
sent all the CpGs crucial for gene silencing [23]. An alter-
native is methylation-specific whole genome sequencing,
but this remains prohibitively costly. In the present study,
we aimed to establish, and provide proof-of-concept for, a
novel strategy assessing the full CpG spectrum across pro-
moter areas of tumor suppressor genes. The assay applies
methylation-specific massive parallel sequencing of the
promoter areas of a panel of 283 tumor suppressor genes.
We show the feasibility of the method by depicting pro-
moter methylation variation across the promoter panel in
a set of white blood cell (WBC) DNA obtained from 34
healthy individuals. Further, by performing an exploratory
hierarchical clustering, our findings indicate that the pro-
files of normal cell promoter methylation of tumor sup-
pressor genes fall into two main clusters defined by
differences in genes regulating key biological pathways.
Results
Methylation specific sequencing
We analyzed WBC DNA from 34 healthy individuals.
After bisulfite conversion of the DNA, we performed
methylation-specific sequencing of 565 capture regions
representing 356 target regions from 283 tumor suppres-
sor gene promoters (the full list of genes and regions is
presented as Supplementary Table S1). Sequencing was
performed on an Illumina MiSeq, running 8 samples per
run. Regarding average values per sample, we obtained
4.95 × 106 reads (range 3.36-7.85 × 106) (Fig. 1a; for de-
tails per sample see Table 1). Subsequent to quality fil-
tering, 88% of the reads, were retained. Thus, after
filtering, 4.30 × 106 reads were attempted mapped to the
genome, yielding 4.08 × 106 mapped single reads. Out of
these, 3.6 × 106 reads mapped with properly paired reads
for each sample (average values; Fig. 1a). These reads led
to a mean primary target coverage of 189.6x (114.8x-
269.5x) and a mean capture target coverage of 199.4x
(120.7x-283.4x). Every sample had almost equal
Poduval et al. Clinical Epigenetics          (2020) 12:131 Page 2 of 15
percentage of reads mapped to capture targets and pri-
mary targets (Fig. 1b).
The overall number of informative CpGs identified for
each sample were on average 1.0 × 105 (range 0.9 × 105
to 1.6 × 105). Restricting the CpGs to those with a
methylation ratio > 0, and more than 10 reads in cover-
age, the number was reduced to 1.5 × 104 (range 1.1 ×
104-1.9 × 104; Fig. 1c).
We defined the sensitivity of our strategy as 1/x, where
x = sequencing depth at any given CpG. With the aver-
age primary target depth being 189.6x, the sensitivity
was 0.53%. In theory, the fragility of this sensitivity esti-
mate lies in that, for some samples, the results may de-
pend on a single read, rendering them more sensitive to
artifacts such as inadequate bisulfite conversion. How-
ever, assessing the bisulfite conversion rate (C to T) of
the internal Lambda DNA control (see the “Methods”
section), we found the conversion efficiency to be on
average 99.7% (range 99.6-99.8%) across the analyzed
samples (Fig. 1d). This indicates a rate of technical arti-
facts (falsely retained C’s instead of T’s) to be lower than
0.2-0.4%, thus approaching the error rate in the sequen-
cing per se (Q30 threshold).
Reproducibility was assessed in a separate standard
sample (pooled DNA from 5 healthy donors) that was
run in 6 parallels per run over 2 independent runs. In a
selection of 12 out of the 565 regions, we found the
mean coefficient of variation to be 7.1% (median 4.4%;
Supplementary Table S2). As such, the technical vari-
ability in this standard sample was considerably lower
than the detected biological variation (see below) in our
study set of 34. Variability was considerably lower when
assessing all CpGs in a region than when limiting ana-
lyses to randomized selections of CpGs within the re-
gions (e.g., for PRDM2, the coefficient of variation was
1.5% when considering all CpGs while it was on average
4.7% when assessing randomized selections of 5 CpGs
within the region).
Methylation landscape of tumor suppressors
For each sample, we calculated the mean methylation
for each of the 565 capture regions based on individual
CpG methylation ratios within each actual region (see
the “Methods” section for details). We observed large
Fig. 1 a Output reads from methylation specific targeted
sequencing. Bars indicate the output yield in terms of number of
reads (millions) for each of the analyzed individuals. Blue bars
indicate the total number of reads, while red bars indicate number
of reads mapping to the genome. b Percentage of mapped reads
on primary (blue) and capture target regions (red) for each sample. c
Number of CpGs called in the analyzed samples. Blue bars show
identified CpGs and red bars show CpGs with > 10 reads in all
samples and a non-zero methylation ratio. d Bisulfite conversion
efficiency (> 99.5% recommended; dotted line) for each sample
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inter-region variation in the methylation levels of the re-
gions within the 283 tumor suppressor gene promoters
analyzed (Fig. 2). Some regions were completely methyl-
ated (e.g., regions within the promoters of AIP, PRDM2,
ATR, DICER1, SFPQ), while others in general were non-
methylated in most individuals (e.g., regions within
ARID2, TRIM33, SETD2, IKZF1, and ARID1B; Supple-
mentary Figure 1).
In some regions, there was a large variability between
CpGs within the promoter region, indicating that some
CpGs may be constitutively methylated, while others
(perhaps more crucial for transcriptional regulation) had
a lower methylation level and may be more dynamically
methylated (Supplementary Figure 2).
Constitutional promoter hyper-methylation has been
classified either as secondary due to a rare genetic/SNP
variant [16], typically resulting in high methylation levels
[31, 32] or primary, in which case, methylation may
occur at a low mosaic level (VAF of < 10%) [23]. As for
both cases, we may not expect identifying several
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10046_S2 5043578 90.39 78.71 3588074 54.01 54.31 209.99 220.84
10071_S7 5167738 89.08 83.62 3849392 44.54 44.81 186.40 196.12
10077_S3 4622790 90.13 81.18 3382228 52.35 52.66 198.17 208.34
10078_S8 4148304 89.91 83.59 3117970 33.13 50.13 175.26 184.27
10081_S4 4408742 89.53 81.99 3236368 50.31 50.60 186.37 195.79
10082_S5 4146244 88.90 82.83 3053058 48.82 49.10 171.00 179.62
10086_S6 4665150 89.39 80.91 3373894 49.76 50.06 186.09 195.68
10088_S2 5683572 88.12 83.26 4169990 49.01 49.29 219.04 230.48
10097_S3 5372752 87.46 84.09 3951544 44.74 45.00 195.13 205.17
10107_S1 4659718 89.67 80.24 3352898 55.68 56.00 213.95 224.78
10110_S6 5369964 86.87 82.21 3835038 47.17 47.45 199.76 210.11
10113_S7 3862862 89.44 83.54 2886124 36.11 36.31 120.48 126.52
10117_S5 4243470 89.93 85.80 3274194 46.15 46.42 169.10 177.78
10126_S7 5490894 87.68 83.36 4013294 44.39 44.65 198.79 209.00
10131_S1 5338282 87.00 82.62 3836988 53.58 53.88 232.54 244.35
10146_S6 4326882 90.13 85.57 3337118 45.47 45.73 168.34 177.00
10149_S7 4129130 90.01 84.46 3139126 45.78 46.04 159.55 167.77
10155_S5 4450890 86.31 84.99 3264796 46.65 46.91 170.60 179.37
20011_S4 5923516 87.27 85.49 4419628 41.19 41.42 203.82 214.20
20019_S1 3972578 89.46 84.62 3007020 49.39 49.68 163.80 172.27
20022_S4 7091616 88.48 81.02 5083584 47.19 47.47 257.88 271.25
20023_S1 7854298 88.16 81.78 5662728 43.72 43.98 269.47 283.35
20024_S5 6284900 88.04 82.23 4549698 41.85 42.09 215.05 225.92
20062_S2 3554848 88.54 84.13 2648098 40.36 40.54 127.76 133.78
20068_S3 3355298 89.51 84.38 2534292 48.89 49.18 138.43 145.54
20078_S2 7541786 88.33 84.85 5651984 38.94 39.16 246.67 259.20
20088_S4 4083996 90.28 84.33 3109332 33.27 33.46 114.79 120.70
20092_S3 4686060 89.01 83.38 3477852 50.58 50.88 196.38 206.39
20098_S1 4501632 88.21 83.23 3305210 53.58 53.89 197.69 207.78
20106_S2 4430250 86.96 83.43 3214408 45.12 45.32 173.69 181.84
20117_S4 4802994 88.70 86.01 3664364 44.22 44.48 178.18 187.37
20119_S5 4525080 89.19 85.57 3453670 46.90 47.16 180.35 189.59
20122_S6 4741150 88.79 85.18 3585870 51.76 52.07 204.62 215.16
20160_S3 5848296 88.30 84.30 4353508 46.02 46.28 220.04 231.29
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affected individuals in a small dataset like the present;
thus, lack of differential methylation here may not ex-
clude a gene as a potential epigenetic pathogenic factor.
Still, to validate the feasibility of our method, we aimed
at exploring potential differential methylation between
individuals across our data set. To do so, we took three
approaches: first, we assessed differential methylation
across the dataset in general. Second, we specifically
assessed for individual hyper-methylation, assuming this
to be the most relevant alteration regarding inactivating
tumor suppressors. Third, we specifically assessed those
tumor suppressors where previous data have linked pro-
moter methylation to cancer risk.
Differential methylation
Subsequent to methylation calling, we identified pro-
moter regions differentially methylated across our sam-
ple set. Although low levels of methylation (allele
methylation frequency of < 5%) have been shown to
affect cancer risk [23], in the present sample set we fo-
cused on identifying those genes presenting the largest
inter individual methylation variation as a proof-of-
concept for our methodological approach. We defined
methylation variation in a region according to the differ-
ence in absolute but also relative methylation level. First,
we assessed the difference in absolute methylation as the
difference in percentage of alleles methylated between
individual (i.e., difference presented as percent points).
Second, we assessed the relative difference between indi-
viduals, i.e., the ratio between the highest and lowest
methylated individual with respect to percentage of
methylated alleles.
Based on a Z-score assessment of a methylation matrix
consisting of averaged methylation ratios for each of the
565 capture regions across all 34 samples (see the
“Methods” section for details), we identified 206 regions
(within the promoters of 149 genes) where a minority
(one-third or less) of the samples analyzed were signifi-
cantly differentially methylated as compared to the ma-
jority of samples at a ≥ 99% confidence level (i.e., outside
the 99% confidence interval; Supplementary Table S3).
Assessing the difference between the samples with the
highest and the lowest level of methylation within these
206 regions, about half of the regions (n = 101) displayed
less than 5 percent point difference. However, several of
the tumor suppressor regions displayed a large variation
in methylation, with 72 regions displaying > 10 percent
point difference and 22 regions displaying > 20 percent
points difference between the highest and the lowest
methylated samples (Table 2). The largest difference was
observed for GAS7, where the difference between the
highest and the lowest methylated sample was 66.6 per-
cent points.
Fig. 2 Heatmap showing average methylation ratio for all samples
and genes. Scale: Red indicates high methylation and blue indicate
low methylation
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Assessing the relative difference (ratio between the high-
est and lowest methylated sample), again GAS7 was the
top-ranking promoter, showing a relative difference of 3.5
fold between the highest and the lowest methylated sam-
ple. As expected, in addition to GAS7, we found a substan-
tial overlap between top-ranking regions based on
absolute differences and the top-ranking regions based on
relative differences (ratio) in methylation levels (Table 2).
Especially the AIP gene also had a region that was highly
differentially methylated both in terms of percentage dif-
ference (> 20%) and fold difference (> 3 fold). The only re-
gions with less than 20 percent point difference but a high
fold difference (> 2 fold), were regions in RABEP1, RASS
F1, AIP, and FOXO4 (Table 2, lower section).
Hyper-methylated tumor suppressors
Regarding tumor suppressor genes, we hypothesized that
in case constitutional methylation is associated with a
significantly elevated cancer risk, we may expect a minor
sub-fraction of healthy individuals to have hyper-
methylated promoters. We therefore performed add-
itional sub-analyses restricting 206 genes identified
above, to the genes/region with positive Z-scores with >
99% confidence level, i.e., genes/regions that were
Table 2 Differentially methylated genes. Gene regions with > 20 percent points difference in methylation ratio, between least
methylated sample to most methylated sample along with fold change differences are listed. Hyper-methylated target region of
those genes are shown in bold
Gene name Gene capture region Min. methylation ratio Max. methylation ratio Difference in methylation ratio Fold change
GAS7 chr17: 10199716 - 10200316 0.2670 0.9332 0.6662 3.4951
ELAC2 chr17: 13019069 - 13019845 0.4581 0.8332 0.3751 1.8188
GSTM1 chr1: 109686327 - 109687046 0.6438 1.0000 0.3562 1.5533
THBS1 chr15: 39579298 - 39579871 0.4671 0.7885 0.3214 1.6881
CIITA chr16: 10874982 - 10875928 0.2511 0.5577 0.3066 2.221
RASSF1 chr3: 50339388 - 50340021 0.1786 0.4720 0.2934 2.6428
CHN1 chr2: 174846842 - 174848034 0.2141 0.5074 0.2933 2.3699
MSH2 chr2: 47401613 - 47402319 0.5897 0.8734 0.2838 1.4811
PALB2 chr16: 23642511 - 23643136 0.6333 0.9134 0.2801 1.4423
RUNX3 chr1: 24964233 - 24965550 0.3920 0.6479 0.2559 1.6528
TP63 chr3: 189789769 - 189790448 0.6612 0.9059 0.2446 1.3701
PDCD1LG2 chr9: 5510022 - 5511326 0.3182 0.5511 0.2330 1.7319
AIP chr11: 67481632 - 67482276 0.6716 0.9002 0.2286 1.3404
GPC3 chrX: 133986729 - 133987434 0.5842 0.8036 0.2194 1.3756
AIP chr11: 67482202 - 67482880 0.1035 0.3214 0.2180 3.1053
GSTP1 chr11: 67581895 - 67582976 0.2673 0.4834 0.2162 1.8085
AIP chr11: 67481257 - 67481869 0.7857 1.0000 0.2143 1.2728
XPA chr9: 97698585 - 97699193 0.6991 0.9130 0.2139 1.306
APC chr5: 112736082 - 112736959 0.6361 0.8479 0.2118 1.333
CTCFL chr20: 57524096 - 57527440 0.6554 0.8663 0.2109 1.3218
CASP8 chr2: 201259179 - 201260169 0.3698 0.5799 0.2102 1.5681
ZNF668 chr16: 31064314 - 31065859 0.4513 0.6584 0.2070 1.4589
-- -- -- -- -- --
RABEP1 chr17: 5281240 - 5283045 0.0415 0.1033 0.0618 2.4902
AIP chr11: 67482382 - 67483805 0.0517 0.1229 0.0712 2.3783
RASSF1 chr3: 50338258 - 50339618 0.0976 0.2178 0.1202 2.2322
FOXO4 chrX: 71094692 - 71096928 0.1256 0.2592 0.1335 2.0629
ZRSR2 chrX: 15789350 - 15791219 0.0559 0.1021 0.0462 1.8252
RUNX1T1 chr8: 92102449 - 92105016 0.0558 0.1008 0.0450 1.8068
RHOH chr4: 40196452 - 40197679 0.1059 0.1914 0.0855 1.8067
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significantly hyper-methylated in a minority of individ-
uals as compared to the majority of individuals (see the
“Methods” section). Among the 206 differentially meth-
ylated regions, 115 revealed positive Z-scores. Out of
these 115, 25 displayed > 10 percent points difference
from the highest to the lowest methylated sample. The
corresponding number of regions revealing > 20 percent
points difference was 7. These 7 regions were within the
promoters of CIITA, RASSF1, CHN1, PDCD1LG2,
GSTP1, XPA, and ZNF668, with the three former genes
revealing a difference of more than 30 percent points
(Table 2). Re-assessing these data based on fold differ-
ence instead of percent points, we identified three re-
gions (in AIP, RABEP1, and RASSF1) with a lower than
20 percent point absolute difference but a relative ratio
> 2. Since another region of RASSF1 was already identi-
fied as having a difference > 20 percent points, this left
us with 9 different genes with substantial differences in
methylation levels.
Further, we reasoned that if methylation of any of
these genes may act as a cancer risk factor, then somatic
methylation of the same genes should be present in a
fraction of human cancers. We therefore mined the
COSMIC data base [33] for reported somatic methyla-
tion of the 9 genes. Six of these genes (CHN1,
PDCD1LG2, XPA, ZNF668, RABEP1, AIP) were not re-
ported to be aberrantly somatically methylated in tu-
mors, while one gene (CIITA) was reported to be hypo-
methylated in a very small fraction (0.19-1.53%) of vari-
ous solid tumors. In contrast, somatic hyper-methylation
of RASSF1 was reported in > 4% of endometrial cancers
and > 1% of breast cancers. Further, somatic hyper-
methylation of GSTP1 was reported in > 7% of prostate
cancers and > 1% of breast cancers. Thus, this finding
indicates that some genes found hyper-methylated in
tumor tissue are also differentially methylated in normal
tissue of healthy individuals. Although these data do not
provide any conclusive evidence per se, the findings war-
rant further investigations exploring constitutional
methylation as a potential cause of cancer risk.
Methylation in established cancer risk genes
Among some of the best-characterized cancer risk genes
in terms of mutations (BRCA1, TP53, and RB1), we
found the mean methylation level to be 0.7% in the
known regulatory region of the BRCA1 promoter, in line
with our previous findings [23]. For TP53, the mean
methylation level was 7.9%, while the corresponding
number for RB1 was 24.9%. For some additional genes
where methylation has been found as a cancer risk fac-
tor, MLH1 and MGMT, these revealed mean methyla-
tion levels of 6.4% and 18.6%, respectively. Among these
established cancer risk genes (BRCA1, TP53, RB1,
MLH1, and MGMT), we found no significant differences
between the individuals in the present data set.
Co-methylated tumor suppressors
The cause of differential DNA methylation, and, in par-
ticular, tumor suppressor promoter methylation, remains
poorly understood. Thus, in an exploratory analysis, we
assessed potential covariation between promoter methy-
lation on an individual basis. For this purpose, we per-
formed hierarchical clustering of the samples by
applying the Z-scores from average methylation ratio
across the 565 capture regions. Doing so, all samples
could be classified into two distinct major clusters, each
harboring distinguishable sub-clusters (Fig. 2). Interest-
ingly, the two major clusters (1 and 2) were character-
ized by different promoter methylation in two groups of
genes (A and B), where cluster 1 had high methylation
in genes in group A and low methylation in genes in
group B, while the opposite methylation pattern was
seen for samples in cluster 2 (Fig. 2).
We identified genes falling into these two groups
(A and B), and analyzed their involvement in func-
tional pathways by KEGG pathway analysis and GO
enrichment analysis via Gather. Many of the genes in-
volved in group A were important in development
and regulation of cellular processes like Wnt signaling
and TGF-beta signaling pathways. In contrast, genes
from group B showed involvement in apoptotic path-
ways and leukocyte differentiation (Supplementary
Table S4).
Notably, some individuals were characterized by hav-
ing a majority of genes either hyper- or hypo-methylated
as compared to the rest of individuals. Applying a 95%
confidence interval across samples with respect to the
overall methylation level of the regions analyzed, one
sample (S24) fell below the lower limit of the CI, while
three fell above the upper limit of the CI (Supplementary
Figure 3). However, these individuals were distributed
across the two main clusters with no preference for one
group over the other. Assessing the available general
clinical data for these individuals, no notable associa-
tions were observed between methylation and factors
such as age or BMI (data not shown).
Validations in external data sets
Although our data are unique since they are generated
by targeted massive parallel sequencing analyses, we
sought to validate our biological findings by mining
available data sets generated by application of methyla-
tion arrays.
A technical concern is that methylation could poten-
tially vary between subfractions of leukocytes and differ-
ential methylation between individuals could then
potentially be a result of individuals having different
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compositions of leukocyte subfractions in their blood.
Assessing the 7 most differentially methylated regions in
our data set, in the leukocyte subfractions published in
the Bioconductor Experiment Data Package FlowSorted.-
Blood.450K revealed no major difference in any of the 7
regions (Supplementary Table S5, with figures). In
GSTP1, 6 out of 19 CpGs revealed lower methylation in
CD14+ T cells and/or CD56+ NK cells than other sub-
fractions, but the impact of this on the average levels in
total WBC was negligible. Very similar observations
were made in another data set of cord blood (R package
FlowSorted. CordBlood Norway.450 K in Bioconductor
[34]; Supplementary Table S6, with figures). This con-
firmed potentially varying composition of leukocyte sub-
fractions not to be a likely cause of the observed
methylation differences.
Further, we sought to validate the biological differences
observed for the 7 most differentially methylated regions
in our sample set, by assessing their methylation in a sam-
ple of blood DNA from 845 individuals (GSE51032). In
this sample set, data was available for CHN1, PDCD1LG2,
GSTP1, and ZNF668. In addition, we here included the
two top-ranking genes with high differential methylation
calculated as ratio, but where percent point difference was
below 20 (see above; RABEP1 and AIP; Table 2). In gen-
eral, the methylation levels were called as slightly higher
in the GSE51032 set than by our own sequencing. How-
ever, the differences between individuals were confirmed
for all genes and the difference in percent points between
the highest and lowest methylated individual was similar
(Supplementary Table S7). The exception was ZNF668,
where our maximum observation was 66% methylation,
while in the GSE51032 set, some individuals were scored
as 100% methylated. This difference probably relates to a
substantially higher number of individuals analyzed in the
validation set increasing the chance of observing outliers.
Discussion
While to this end constitutional epimutations of tumor
suppressors have been linked to cancer risk for a few
genes only [23, 27, 31, 35–37], one may postulate that
constitutional epimutations affect other tumor suppres-
sors as well. This may have implications to our under-
standing of cancer risk. A substantial number of cancer-
prone families in which no underlying germline muta-
tion have been identified, and it is tempting to postulate
that some of these individuals may be at increased can-
cer risk due to constitutional epimutations in tumor
suppressor genes [30]. In addition, germline mutations
in several tumor suppressor genes have been associated
with other conditions such as skin and limb develop-
ment deficiencies, Cowden syndrome, and Fanconi
anemia [38–40]. Thus, exploring constitutional
promoter methylation across tumor suppressor genes
may be of importance to other medical conditions as
well.
To this end, the vast majority of epigenetic data re-
ported in respect to different health conditions are based
on global methylation-array analyses or single gene pro-
moter analyses by methods like MSP or MLPA. While
the array-based approaches do provide data for single
CpGs, a large number of (potentially important) CpGs
are lacking from the arrays, limiting the possibilities to
identify methylation pattern across all regions of interest
(e.g., as seen for BRCA1 [23]). As for MSP and MLPA,
such methods are fast and cheap but they are sensitive
only to a general methylation presence in the CpGs cov-
ered by the primers and probes, precluding assessment
at a single CpG resolution level.
Here, we established a massive parallel sequencing-
based approach, enabling base-pair resolution analyses
of methylation status in gene promoters. The method
provides several advantages as compared to previous
methods. First, as compared to conventional methods
like MSP and MLPA, our method allows for detailed
single-CpG resolution analyses of multiple promoter re-
gions in concert. Second, our method limits both work-
load and costs compared to application whole-genome
methylation sequencing for promoter methylation ana-
lysis. Third, the benefit of determining exact methylation
levels, instead of binary assessments, has been confirmed
in clinical studies [23], underlining the importance of
high sensitivity required to detect low-grade mosaic
methylation [30]. Fourth, as compared to available array-
based approaches, our NGS-assay allows for methylation
assessment of all CpGs in the region of interest, not only
those covered by array probes. As mentioned above, this
proved to be crucial in analyses of the cancer risk associ-
ated with mosaic BRCA1 methylation [23].
In principle, the sequencing of the DNA-libraries we
prepared could be run on any Illumina instrument. As
such, the method is flexible and scalable. Here, we used
the MiSeq instrument due to the rapid run time. In our
set-up, we chose to run 8 samples in one run, yielding
an average coverage of 189.6x, corresponding to a mean
sensitivity limit of 0.53%. Although indicating a very sen-
sitive method, this is an average value, and some regions
reveal lower coverage. If needed, however, coverage
could be increased in order to improve the sensitivity of
the method [23]. Notably, the reproducibility of the
assay may vary between the different covered regions.
However, we show that the reproducibility is very
good even in regions with low levels of methylation.
Importantly, the observed technical variation was con-
sistently negligible compared to the biological varia-
tions described. Further, we found that technical
variations were lower when assessing all CpGs across
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a given region than when assessing randomized selec-
tions of CpGs as “representative” for a region. This
emphasizes the value of applying assays where all
CpGs in a given region are covered, instead of relying
on scattered, selected CpGs.
While constitutional methylation is considered an
early life event affecting different germinal layers, methy-
lation status is also prone to environmental influences
and other factors and has been found to change during
lifetime [41], causing differential methylation of many
genes across different tissues [42]. One potentially im-
portant caveat when analyzing WBCs as surrogate
markers for constitutional methylation is the fact that
different leukocyte fractions may harbor different methy-
lation patterns [43]. While such differences, so far, have
been linked to global methylation patterns, it remains
unclear whether this may represent a problem with re-
spect to specific tumor suppressor methylation. Notably,
differential methylation across WBC subfractions was
found not be an issue regarding BRCA1 promoter
methylation [23], and in the present study, it was not
found to be an issue in the most differentially methyl-
ated promoter regions either.
The methylation level of the genes found to confer
cancer risk, so far, is highly variable. Regarding MLH1,
normal cell methylation affecting ~ 50% of the alleles
has been reported in a limited number of probands with
familial colorectal cancer (for original references, see
[30]). Recently, two families with a high breast and ovar-
ian cancer incidence were found to harbor secondary
constitutional BRCA1 methylation, also with a methyla-
tion level of ~ 50% [31]. In contrast, about 4% of females
in a Caucasian population was found to carry low-level
mosaic constitutional BRCA1 methylation (4-10% of al-
leles). Among these low-level methylated individuals, the
incidence of high-grade serous ovarian cancer was sig-
nificantly elevated with an odds ratio between 2 and 3
across two large cohorts [23]. As for the method pre-
sented here, this has the sensitivity required for explor-
ing both scenarios.
While the limited number of samples analyzed pre-
cludes formal assessments of methylation frequency
and/or potential correlations to health outcome, import-
antly, our findings confirm differential constitutional
promoter methylation across a panel of tumor suppres-
sor genes in healthy individuals. Interestingly, among
those promoter regions found to be hyper-methylated in
the normal tissue of some of the analyzed individuals,
we found promoters in genes previously reported to be
hyper-methylated in tumors (such as RASSF1 and
GSTP1). The presence of epigenetic deregulation of a
distinct tumor suppressor at the somatic (tumor) level
provides no evidence for constitutional methylation of
the same gene. However, the examples related to MLH1
and BRCA1 suggest that potential relationships may
occur for other genes as well. Thus, it is tempting to
speculate that, at least some of the genes detected here
(e.g., RASSF1 and GSTP1) could be constitutionally
methylated and, in such cases, methylated tumor cells
may have originated from the constitutionally methyl-
ated normal cells [30]. Notably, although not directly
comparable to our data, due to a restricted selection of
CpGs covered, mining of a large external data set re-
vealed similar interindividual differences largely confirm-
ing our findings.
Interestingly the methylation patterns revealed across
our gene panel indicated that the individuals analyzed
could be classified into two different methylation clus-
ters. These findings should be interpreted with caution
due to the limited number of individuals analyzed. How-
ever, the fact that the clusters were separated by differ-
ential methylation across important biological pathways
involving Wnt- and TGF-beta signaling pathways as well
as genes involved in apoptotic pathways and leukocyte
differentiation indicate potential underlying biological
differences to be explored in future studies.
Conclusions
We provide a relatively fast and affordable strategy for
detailed assessments of differential methylation of tumor
suppressors. This strategy is attractive in the warranted
search for additional tumor suppressors that may be
cancer risk factors when methylated in normal tissues.
Methods
Samples
The samples analyzed in the present study were from 34
individuals, selected from a set of 114 healthy postmeno-
pausal women previously described [44]. Subsequent to
providing informed consent, each individual donated
anonymized blood samples in accordance with Norwe-
gian regulations. All women were recruited during rou-
tine mammographic screening at Haukeland University
Hospital, Bergen, Norway. Individuals with diabetes or
other types of endocrine diseases as well as individuals
using hormone replacement therapy were excluded. All
samples were drawn > 2 years after the last menstrual
period. Within the selection of 34 individuals analyzed
in the present study, the mean age was 64 years (range
56-71 years) and the mean BMI was 24.8 (range 19.4-
39.6) at the time of sample collection.
DNA isolation
Genomic DNA was extracted from EDTA-whole blood,
using QIAamp DNA Mini kit (Qiagen). The procedure
was performed according to the manufacturer’s instruc-
tions with the exception that 400 μl of whole blood was
used as input.
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Selection of tumor suppressor promoter regions
Regions of interest were defined as 356 regions from the
promoters of 283 tumor suppressor genes. The selection
of genes was based on the cancer gene panel previously
described as “CGPv2/3” [45, 46], Roche’s “Comprehen-
sive Cancer Design” as well as a manual literature re-
view, in order to cover all well-established tumor
suppressor genes, independent of cancer type. As such,
the selection was independent of previous knowledge
about methylation status. For each transcription start
site (TSS), we designed probes covering a region span-
ning from −1500 to +500 relative to TSS. Positions of
TSS were determined by NCBI and Ensembl-curated
transcripts, literature search, and use of the FANTOM5
RNA expression resource (fantom.gsc.riken.jp/5/).
Probes for hybridization to the included regions were
manufactured by Roche and designed to bind the target
DNA of all possible methylation configurations (fully
methylated, partially methylated, and completely
unmethylated). Importantly, both strands were targeted,
in order to enable correction for potential overlap be-
tween CpGs and SNPs. By probe design, the 356 target
regions were split into 565 capture regions. Full lists of
included tumor suppressor genes and target regions are
given in Supplementary Table S1.
Library preparation and methylation sequencing
Processing of the sample libraries was performed using
the solution-based bead capture method for enrichment
of bisulfite-converted DNA, SeqCap Epi Enrichment Sys-
tem (Roche) according to the user guide (version 1.2).
For each sample, 1 μg DNA isolated from blood was
mixed with bisulfite-conversion control (Lambda DNA,
negative for methylation). DNA was fragmented to the
range of 180-220 bp using Covaris M220 followed by
end repair, A-tailing, ligation of index/adapters, and dual
size selection. Using the Zymo Research EZ DNA
Methylation-Lightning kit, the DNA was bisulfite-
converted according to manufactures protocol, and the
resulting sample was amplified prior to nanodrop quan-
tification. Based on these measurements, 1 μg bisulfite-
converted DNA was put into the hybridization with
custom-made probes for 68 h prior to capture by
streptavidin-coated beads, extensive washing, and a final
library amplification step.
The protocol was combined with the use of a custom-
made probe design enabling analysis of only regions of
interest (consisting of 356 promoter regions from 283
tumor suppressor genes, described above and in Supple-
mentary Table S1). In addition, the probe set included
probes targeting (Lambda DNA for conversion control).
The targeted regions were enriched by a bead capturing
method that captures both strands of DNA. Purified li-
braries were pooled, spiked with 10% PhiX, and
sequenced on an Illumina MiSeq sequencer, using v2
chemistry and 2 × 100 (200 cycles) paired-end reads.
RTA v1.18.54 and MCS v2.5.0.5 software was used to
generate data. Eight samples were multiplexed per run,
and resulting data were de-multiplexed based on
sample-specific indexes attached to the sequencing
adaptors. De-multiplexing was run automatically by the
MiSeq Reporter software before further processing.
Methylation calling
Raw sequencing data was analyzed using an in-house
workflow designed in collaboration with Roche, com-
prised of publicly available tools, implemented using
shell script (Fig. 3; for a detailed description see Supple-
mentary information). In brief, the first analytic steps in-
volved quality checking of fastq files by FASTQC.
Paired-end reads were filtered based on quality and
clipped using Trimmomatic [47]. Trimmed sequences
were aligned to the human genome (GRCh38) from
NCBI as well as Enterobacteria phage lambda (NC_
001416.1) complete genome, added for bisulfite conver-
sion efficiency control using the bisulfite mapping algo-
rithm BSMAP [48]. The aligned read statistics and
format conversions were carried out using SAMtools
[49]. After bisulfite conversion, the DNA strands are no
longer complementary. To achieve methylation informa-
tion from both strands, aligned reads were split into the
top and bottom strand [50]. Subsequently, the sequences
were sorted, and duplicates were removed and merged
back using Picard tools. In the next step, the analysis
was further restricted to those read pairs where both
mates in the pair could be mapped in the correct orien-
tation and at given distance consistent with the library
insert size (properly paired reads) using BamTools [51].
To avoid bias, overlapping reads were clipped using
BamUtils. Various statistics for reads, alignment, and
coverage were calculated using SamTools.
For each sample, methylation analysis was carried out
using methratio.py package in BSMAP by calculating
methylation percentage. An additional step involves SNP
calling for the targeted regions with BisSNP [52] from
aligned reads.
DNA conversion rate was calculated based on all ori-
ginal Cs in the Lambda DNA sequence. For all Cs in the
untreated sequence the following formula was used on
sequencing data post bisulfite treatment:
Conversion %ð Þ ¼ T= C þ Tð Þ  100
Assay reproducibility
To assess reproducibility of the assay, we performed 2
independent experiments with 6 parallels of a standard
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sample in each experiment. The standard sample con-
sisted of pooled DNA of equal amounts from WBC of 5
healthy donors. Reproducibility was assessed across 12
regions, selected based on three separate criteria: First,
we selected 4 regions found to have high biological vari-
ance in our original sample set of 34 healthy women
(GAS7, ELAC2, AIP, ZRSR2). Further, we selected 6 re-
gions in genes known to be high penetrance genes when
either mutated or hypermethylated (BRCA1, TP53 (2 re-
gions), RB1, MLH1, MGMT). Finally, we selected 2
regions at random (PRDM2, TMEFF2). Based on the 12
replicate analyses, we calculated mean methylation,
standard deviation and coefficient of variation for all the
regions (Supplementary Table S2a). Further, within the
2 randomly selected genes (PRDM2, TMEFF2), we per-
formed a randomized selection of 5 CpGs per region,
using the mean methylation in these 5 as “representa-
tive” for the region. Then, we calculated mean methyla-
tion, standard deviation and coefficient of variation
across the 12 replicate analyses of these 5 CpGs. This
Fig. 3 Workflow of the methylation analysis. Flow chart of the steps taken within the informatics analysis pipeline from raw FastQ files to
processed data used for biological interpretations. Main steps are indicated by blue background; smaller steps are indicated by gray background
(figure adapted from original design by Roche)
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randomization was repeated 5 times, yielding a general
overview of the variability when applying limited num-
bers of CpGs as “representative” for a region (Supple-
mentary Table S2b).
Differential methylation assessment
Among all CpGs in the 565 capture regions as well as
250 flanking bps at each end, the analysis was restricted
only to include CpGs with minimum of 10 reads in
coverage in all of the 34 samples. For each sample, we
then calculated the mean methylation per region, based
on individual CpG methylation ratios within the region.
Based on these data, we generated a methylation matrix
for all the common regions across all the samples (n =
34 in the present study), and calculated Z-scores for that
matrix. Then we assessed the Z-scores and identified all
the regions where a minority of individuals were differ-
entially methylated as compared to the majority. Differ-
ential methylation was here defined as Z-scores that
were outside of the 99% confidence interval. We used an
arbitrary definition of minority, set to one-third, or less,
of the total number of samples, i.e., minimum 1 individ-
ual and maximum 12 individuals (this definition may
need adjustment according to the size of subsequent
studies). Regions that had confidence level more than
99% were then categorized into negatively and positively
methylated regions based on the Z-score value and
whether the minority of individuals had higher or lower
methylation levels than the majority.
To find the differentially methylated regions, we calcu-
lated the mean methylation for these regions across
CpGs within individual samples and measured the differ-
ence in methylation between individuals with the lowest
and highest methylation mean. Although relatively small
differences in methylation levels have been shown to
modulate cancer risk [23], we here sought to identify the
regions with larger differences, applying arbitrary thresh-
olds of 5, 10, and 20 percent point difference in methyla-
tion. Further, we performed additional analyses assessing
ratios (fold difference) between individuals, taking into
account that biological important differences may have
high ratios, not necessarily reaching a certain threshold
set by percent point difference (e.g., a difference between
1% and 10% may be important, even if the percent point
difference is only 9).
Hierarchical clustering
We created a matrix of methylation ratios for all genes
across patients. We then calculated a variance for each
gene across patients to identify differential methylation.
Heatmap was produced with heatplot function from
made 4 package [53], with mean linkage cluster analysis
and a correlation metric distance. For the purpose of
clustering, missing values for regions in individual
patients were filled in using the impute R package [54,
55]. (Impute-knn function from impute R package, finds
k-nearest neighbors using a Euclidean metric and uses
their mean to substitute the missing value). Missing
values affected one region of GSTM1 in 16 samples, an-
other region of GSTM1 in 7 samples, and a region of
AIP in 3 samples.
Pathway analysis
We identified groups of genes from cluster analysis and
explored their functional roles by pathway analyses with
GATHER. GATHER is an online platform that predicts
functional molecular patterns and biological context by
incorporation of several biological databases [56]. In
GATHER, we analyzed KEGG pathways and gene ontol-
ogy enrichment analyses [57].
External data sets
We performed data mining and extracted detailed
methylation status for all available CpGs for a given re-
gion (defined by our NGS-panel) from the Bioconductor
Experiment Data Package FlowSorted.Blood.450K
(https://bioconductor.org/packages/release/data/experi-
ment). This data set was generated by methylation array
analyses across 6 independent samples from adult indi-
viduals and contains information on 10 different cat-
egories of leukocytes. The categories include the major
groups of granulocytes and lymphocytes.
We obtained similar data for umbilical cord blood from
newborns [34]. These data were available as the R package
FlowSorted.CordBloodNorway.450K in Bioconductor. This
data set was also based on methylation array and holds in-
formation about 7 categories of leukocytes, including the
major groups of granulocytes and lymphocytes, across 11
independent cord blood samples from newborns.
For validation of methylation differences in blood
DNA from healthy individuals, we mined data from
GSE51032, available through Gene Expression Omnibus
(GEO). This data set was generated by methylation array
and consists of 845 samples from the EPIC-Italy cohort
(out of which 188 were males and 657 were females).
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13148-020-00920-7.
Additional file 1: Supplementary Figure 1. Fraction of methylated
alleles in promoter region of selected tumour suppressor genes. (A)
Regions with high methylation levels across samples from all 34 healthy
individuals. (B) Regions with low methylation levels across the same
samples. Note the different scale on the Y-axis for panel A and B. Data for
AIP were lacking for samples 32, 33, 34 due to low coverage (see details
in Materials and methods). Supplementary Figure 2. Plot examplifying
consistent high and low methylated CpGs in the same promoter, across
patients. Fraction of methylated alleles across CpGs in the promoter re-
gion of RB1 in the two samples S7 and S24 are displayed. These two
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samples were selected because they were the one with highest and low-
est overall methylation across the 283 investigated tumour suppressor
genes, respectively (ref. Supplementary figure 3), and as such should rep-
resent the extremes. Still within the RB1 promoter, they reveal a very simi-
lar pattern of some CpGs being highly methylated, while others are
hardly methylated at all. Supplementary Figure 3. Distribution of over-
all average methylation across 283 tumour suppressor gene promoters in
34 healthy individuals. (A) Bars indicate the average fraction of methyl-
ated alleles for all CpGs covered per patient. Dotted red lines indicate the
upper and lower border of the 95% confidence interval for the average
values per patient (CI for individual observations). Sample S24 falls below
the lower border of the CI, indicating general hypo-methylation. Samples
S4, S8 and S7 fall above the upper border of the CI, indicating general
hyper-methylation. (B) Q-Q plot based on the same data as displayed in
(A). S24 is encircled in green, while S4, S8 and S7 are encircled in red.
Additional file 2: Supplementary information – workflow
Additional file 3: Supplementary Table S1. Pan-cancer panel of 283
tumor suppressor genes for which promoters are included in methylation
analyses. The panel was generated based on CGPv2/3-panels [1], Roche’s
Comprehensive Cancer Design along with manual literature search.
Additional file 4: Supplementary Table S2a. Reproducibility test.
Supplementary Table S2b. Reproducibility test restricted to
randomised CpGs.
Additional file 5: Supplementary Table S3. Genes with >99
confidence level difference in methylation ratio between a minority (one
third or less) of samples versus the majority.
Additional file 6: Supplementary Table S4. groupAB_GE
Additional file 7: Supplementary Table S5. WBC fractions
Additional file 8: Supplementary Table S6. Coord blood
Additional file 9: Supplementary Table S7. EPIC
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